NCT05734040 - Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. | Biotech Hunter

Enrollment

478

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

August 10, 2023

Study Completion Date

January 15, 2024

Conditions

Influenza

Interventions

BIOLOGICAL

OVX836 480µg

One single administration intramuscularly at Day 1

BIOLOGICAL

Fluarix Tetra

One single administration intramuscularly at Day 1

BIOLOGICAL

Afluria Quad

One single administration intramuscularly at Day 1

BIOLOGICAL

Placebo

One single administration intramuscularly at Day 1

Trial Locations (9)

Emeritus Research Sydney, Sydney

Paratus Clinical Research Western Sydney, Sydney

Paratus Clinical Research Central Coast, Kanwal

Emeritus, Melbourne

Paratus Clinical Research Brisbane, Brisbane

Mater Misericordiae Limited, Brisbane

UniSC Clinical Trials Moreton Bay, Morayfield

University of Sunshine Coast, Sippy Downs

CMAX Fusion Clinical Research, Adelaide